Genetics of Primary Ciliary Dyskinesia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

320 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-02-28

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to study DNA sequencings for mutations in a research genetic test panel of genes (which contains all 32 known and/or published genes associated with PCD). The study aims to show that about 70% of PCD patients have biallelic mutations in one of these genes. This project will enroll patients who have already had a clinical evaluation, and have clinical features consistent with PCD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic Study of Patients With Primary Ciliary Dyskinesia

NCT00005650

Primary Ciliary Dyskinesia

COMPLETED

A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials

NCT06172374

Primary Ciliary Dyskinesia

ACTIVE_NOT_RECRUITING

Rare Genetic Disorders of the Breathing Airways

NCT00323167

Kartagener Syndrome Cystic Fibrosis Pseudohypoaldosteronism +1 more

COMPLETED

Genetics of Cardiovascular and Neuromuscular Disease

NCT00138931

Cardiomyopathy Arrhythmia Muscular Dystrophy

RECRUITING

Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols

NCT01375543

Genetic Predisposition

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators have established a Consortium of 9 geographically-dispersed clinical research sites to study rare disease of the airways, including Primary Ciliary Dyskinesia (PCD). PCD is a genetic disorder with defective mucociliary clearance (MCC), sinus and pulmonary disease with chronic infection, and organs located on the wrong side of the body in about 50% of patients (Kartagener Syndrome). Lung disease occurs early in children with PCD, but establishing a diagnosis remains a major challenge, based on the traditional approaches of using electron microscopy and/or ciliary waveform analysis to define abnormalities of ciliary ultrastructure and/or function.

For this study, blood or buccal samples for DNA will be collected and genetic testing in patients with known or suspected PCD will be performed. This study can include term neonates with respiratory distress of unknown etiology and features of PCD, particular laterality defects (situs inversus or heterotaxy). The key hypothesis for this study is that a genetic test panel of 32 genes will confirm a diagnosis in most patients with PCD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Ciliary Dyskinesia Kartagener Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any patient who has ≥ 2 clinical features (+/- lab) characteristic of PCD, including:

* Neonatal respiratory distress after term (or near-term) birth
* and/or laterality defect ( situs inversus or heterotaxy)
* and/or daily wet cough before 6 months of age
* and/or middle ear disease
* and/or chronic nasal congestion before 6 months of age
* and/or bronchiectasis
* and/or male infertility due to sperm tail dysfunction
* and/or low nasal nitric oxide levels (\<77 nanoliters/minute)
* and/or defective ciliary ultrastructure

Exclusion Criteria

* Known diagnosis of cystic fibrosis with classic clinical presentation and elevated sweat chloride levels and/or two known disease-causing Cystic Fibrosis transmembrane conductance regulator (CFTR) mutations, or documented primary or acquired immunodeficiency.
* Known explanation for bronchiectasis (and other clinical features), such as α1-antitrypsin deficiency (ZZ or ZS), inflammatory bowel disease or rheumatoid arthritis.
* Any patient who is unwilling or unable to provide consent or to comply with the testing required in this protocol

A participant should not be in the study if they have not had a standard clinical evaluation to address other potential causes of chronic oto-sino- pulmonary disease.

Eligible Sex

ALL

Accepts Healthy Volunteers

No